Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies, Swisstec Ink Asian Distribution Deal

NEW YORK (GenomeWeb) – Genetic Technologies announced today that it has granted the nonexclusive distribution rights for its genetic screening tests in Asia to Swisstec Health Analytics.

Fitzroy, Australia-based Genetic Technologies offers the BrevaGenplus breast cancer risk assessment test and is developing additional cancer risk assessment products including one for colorectal cancer.

Under the terms of the deal, Swisstec will have the nonexclusive rights to distribute the tests to hospital networks in Asia. In exchange, Genetic Technologies will receive a 5 percent equity stake in Swisstec, and may acquire an additional 5 percent based on the achievement of certain undisclosed milestones. Genetic Technologies has also agreed to provide Swisstec with A$250,000 ($185,238) to facilitate its expansion into China.

The distribution deal comes a little more than month after Genetic Technologies and Swisstec agreed to form a joint venture that will develop a service platform using blockchain technology for medical services and personalized health management. As part of that collaboration, Genetic Technologies will receive a 20 percent stake in Swisstec.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.